In Oct 2007, the FDA introduced that the labeling for all PDE5 inhibitors, like tadalafil, demands a more popular warning with the probable threat of sudden hearing decline as the results of write-up-advertising and marketing stories of temporary deafness linked to use of PDE5 inhibitors.[19] Som